A 31-Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co-Administered With Venlafaxine in Subjects With Major Depressive Disorder (MDD) and Co-Existing Insomnia.

Trial Profile

A 31-Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co-Administered With Venlafaxine in Subjects With Major Depressive Disorder (MDD) and Co-Existing Insomnia.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2012

At a glance

  • Drugs Eszopiclone; Venlafaxine
  • Indications Insomnia; Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms AVERT
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 04 Jul 2012 Planned number of patients changed from 640 to 700 as reported by European Clinical Trials Database record
    • 04 Jul 2012 Pfizer added as associations as reported in the European Clinical Trials Database record
    • 13 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top